FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307142711> ?p ?o ?g. }

• W4307142711 endingPage "e240" @default.
• W4307142711 startingPage "e240" @default.
• W4307142711 abstract "<h3>Purpose/Objective(s)</h3> Among the most serious adverse effects after radiotherapy for prostate cancer is the development of second malignant neoplasms. Recent advances in radiotherapy techniques, such as the introduction of intensity-modulated radiation therapy (IMRT) and proton beam radiotherapy (PBRT), have aimed to reduce exposure to adjacent healthy tissues but may lead to greater bone marrow exposure. Risks for developing myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) but not lymphoid malignancies after radiotherapy have been demonstrated. We quantified risks of hematologic malignancies following IMRT and PBRT compared to 3D conformal radiotherapy (CRT) in a large cohort of prostate cancer patients. <h3>Materials/Methods</h3> This retrospective cohort study used the linkage of Surveillance, Epidemiology, and End Results (SEER) cancer registry data with Medicare claims, including men who were diagnosed with first primary non-metastatic prostate cancer at ages 66-84 years from 2002-2014, received external beam radiotherapy (IMRT, PBRT, or CRT) but no chemotherapy in the first year after diagnosis, and survived ≥2 years after diagnosis without a second primary cancer. Using Cox regression, hazard ratios (HR) and corresponding 95% confidence intervals (CI) were computed to estimate risk of second primary hematologic malignancies, classified into subtypes according to the World Health Organization, after IMRT and PBRT vs CRT. Models were adjusted for age at prostate cancer diagnosis, tumor grade, race, Charlson comorbidity score, and receipt of initial prostate cancer therapy. <h3>Results</h3> The cohort (median follow-up=6.8 years) included 69,966 patients, of whom 23,806 received CRT alone, 43,901 received IMRT without PBRT, and 2,259 received PBRT. A total of 387 patients developed a myeloid malignancy, most commonly MDS/AML, N=291), and 739 developed a lymphoid malignancy, most commonly plasma cell neoplasms (N=178) and diffuse large B-cell lymphoma (N=159). Compared to patients who received CRT, neither IMRT nor PBRT was associated with risk of developing myeloid malignancies overall (IMRT: N=211, HR=0.89, 95%CI 0.70-1.13; PBRT: N=13, HR=0.97, 95%CI 0.55-1.74), with similar results for MDS/AML specifically. Similarly, neither IMRT nor PBRT was associated with risk of developing lymphoid malignancies overall (IMRT: N=390, HR=0.93, 95%CI 0.78-1.11; PBRT: N=24, HR=0.94, 95%CI 0.61-1.43) compared to CRT, with similar results for specific lymphoid malignancy subtypes. <h3>Conclusion</h3> This is among the first cohort studies analyzing risk of hematologic malignancies by subtype after prostate cancer radiotherapy. With longer follow-up and larger sample size compared to previous reports, the hypothesized change in risk for MDS/AML with IMRT/PBRT compared to CRT was not observed. As more data accumulates from patients receiving PBRT, we can gain greater insight into the technique's long-term effects." @default.
• W4307142711 created "2022-10-28" @default.
• W4307142711 creator A5006421521 @default.
• W4307142711 creator A5037180582 @default.
• W4307142711 creator A5039145426 @default.
• W4307142711 creator A5044675556 @default.
• W4307142711 creator A5049111171 @default.
• W4307142711 creator A5060045944 @default.
• W4307142711 creator A5071519135 @default.
• W4307142711 creator A5077309973 @default.
• W4307142711 date "2022-11-01" @default.
• W4307142711 modified "2023-09-28" @default.
• W4307142711 title "Risk for Second Primary Hematologic Malignancies by Radiotherapy Technique in Prostate Cancer Survivors" @default.
• W4307142711 doi "https://doi.org/10.1016/j.ijrobp.2022.07.1209" @default.
• W4307142711 hasPublicationYear "2022" @default.
• W4307142711 type Work @default.
• W4307142711 citedByCount "0" @default.
• W4307142711 crossrefType "journal-article" @default.
• W4307142711 hasAuthorship W4307142711A5006421521 @default.
• W4307142711 hasAuthorship W4307142711A5037180582 @default.
• W4307142711 hasAuthorship W4307142711A5039145426 @default.
• W4307142711 hasAuthorship W4307142711A5044675556 @default.
• W4307142711 hasAuthorship W4307142711A5049111171 @default.
• W4307142711 hasAuthorship W4307142711A5060045944 @default.
• W4307142711 hasAuthorship W4307142711A5071519135 @default.
• W4307142711 hasAuthorship W4307142711A5077309973 @default.
• W4307142711 hasConcept C121608353 @default.
• W4307142711 hasConcept C126322002 @default.
• W4307142711 hasConcept C143998085 @default.
• W4307142711 hasConcept C167135981 @default.
• W4307142711 hasConcept C207103383 @default.
• W4307142711 hasConcept C2778527826 @default.
• W4307142711 hasConcept C2780192828 @default.
• W4307142711 hasConcept C44249647 @default.
• W4307142711 hasConcept C509974204 @default.
• W4307142711 hasConcept C71924100 @default.
• W4307142711 hasConceptScore W4307142711C121608353 @default.
• W4307142711 hasConceptScore W4307142711C126322002 @default.
• W4307142711 hasConceptScore W4307142711C143998085 @default.
• W4307142711 hasConceptScore W4307142711C167135981 @default.
• W4307142711 hasConceptScore W4307142711C207103383 @default.
• W4307142711 hasConceptScore W4307142711C2778527826 @default.
• W4307142711 hasConceptScore W4307142711C2780192828 @default.
• W4307142711 hasConceptScore W4307142711C44249647 @default.
• W4307142711 hasConceptScore W4307142711C509974204 @default.
• W4307142711 hasConceptScore W4307142711C71924100 @default.
• W4307142711 hasIssue "3" @default.
• W4307142711 hasLocation W43071427111 @default.
• W4307142711 hasOpenAccess W4307142711 @default.
• W4307142711 hasPrimaryLocation W43071427111 @default.
• W4307142711 hasRelatedWork W1985607582 @default.
• W4307142711 hasRelatedWork W2012212168 @default.
• W4307142711 hasRelatedWork W2084898420 @default.
• W4307142711 hasRelatedWork W2118934235 @default.
• W4307142711 hasRelatedWork W2164605844 @default.
• W4307142711 hasRelatedWork W2216326174 @default.
• W4307142711 hasRelatedWork W2297983754 @default.
• W4307142711 hasRelatedWork W2300979116 @default.
• W4307142711 hasRelatedWork W2321033326 @default.
• W4307142711 hasRelatedWork W2945969623 @default.
• W4307142711 hasVolume "114" @default.
• W4307142711 isParatext "false" @default.
• W4307142711 isRetracted "false" @default.
• W4307142711 workType "article" @default.